EGFR and non-small cell lung carcinoma: Because a phase II study in elderly advanced patients with NSCLC with EGFR mutations demonstrated similar efficacy and toxicity of gefitinib [10] as previous studies of gefitinib including younger patients [5, 6], gefitinib has been recommended as a first-line treatment option for elderly patients.